To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
Peter Ulrichts
Chief Scientific Officer
Peter Ulrichts is the Chief Scientific Officer at argenx and joined the company in 2010. In this role, he oversees the development of all clinical and pre-clinical compounds within argenx’s pipeline.
Peter joined the company as a research scientist, where he was involved in the development of various therapeutic antibodies for the treatment of cancer and autoimmune diseases. While at argenx, he headed the development of argenx’ FcRn antagonist efgartigimod until the first-in-human study, after which he transitioned to become the lead scientist of the efgartigimod program.
Peter holds a B.S. in Chemistry from KU Leuven as well as an M.S. in Biotechnology and a Ph.D. in Immunology, both from the University of Ghent (Belgium).
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Grants
Funding research, education, and initiatives that raise the standard of care.
About Us
Discover why we’re more than a unique name.
Newsroom
The latest news and press releases from argenx.
